Effect of ixekizumab treatment on scalp psoriasis: Results from a phase 2 study in patients with moderate to severe psoriasis - 16/03/14
Richard Langley, MD, Dalhouise University, Halifax, Nova Scotia, Canada; Baojin Zhu, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Craig Leonardi, MD, St. Louis University School of Medicine, St. Louis, MO, United States; Emily Edson-Heredia, MPH, Eli Lilly and Company, Indianapolis, IN, United States; Gregory Cameron, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Janelle Erickson, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Michael Heffernan, MD, Eli Lilly and Company, Indianapolis, IN, United States; Tomoko Maeda-Chubachi, MD, PhD, Eli Lilly and Company, Indianapolis, IN, United States
Le texte complet de cet article est disponible en PDF.| Sponsored 100% by Eli Lilly and Company. |
Vol 70 - N° 5S1
P. AB168 - mai 2014 Retour au numéro
Article précédent
- Educating patients as to psoriasis treatment options
- Effect of once-daily calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamo-pituitary-adrenal (HPA) axis and calcium metabolism in adolescents with extensive scalp psoriasis: An open, noncontrolled, 8-week trial
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?